Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2020-04-08 Major Shareholding Noti…
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, specifically regarding major shareholding thresholds and collateral agreements. This falls under the 'Major Shareholding Notification' category.
2020-04-08 Korean
사업보고서 (2019.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Business Report' (사업보고서) for the fiscal year 2019, covering the period from January 1, 2019, to December 31, 2019. It includes detailed financial information, company overview, business operations, capital structure, and management details. This is the standard Korean regulatory filing equivalent to a 10-K annual report. FY 2019
2020-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과), detailing the approval of financial statements, dividend resolutions, and the election of directors and auditors. This falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2020-03-26 Korean
본점소재지변경
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding a change in the company's headquarters location (본점소재지변경). It does not fit into specific categories like financial reports, dividends, or share transactions. As it is a standard regulatory disclosure of corporate information, it falls under the fallback category for general regulatory announcements.
2020-03-26 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's representative director (CEO). It details the appointment of a new co-CEO, the reasons for the change, the date of the board resolution, and the professional background of the individuals involved. This aligns perfectly with the definition for Board/Management Information (MANG).
2020-03-26 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form in South Korea (DART system) used when an executive or major shareholder changes their stake in the company, often due to appointment, resignation, or trading. Since this document specifically details the change in share ownership by an executive (Hahn Mi Kyoung) due to resignation, it falls under the category of Director's Dealing (DIRS).
2020-03-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.